Feedback
Settings

Settings

Goto Application

1. WO2003000281 - NEUROPROTECTION AND/OR NEURORESTORATION VIA THE NEURAL AVTIVIN TYPE IIB RECEPTOR

PermaLink
Publication Number WO/2003/000281
Publication Date 03.01.2003
International Application No. PCT/US2002/020111
International Filing Date 21.06.2002
Chapter 2 Demand Filed 17.01.2003
IPC
A61K 31/395 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/44 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
A61K 31/445 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
A61K 31/565 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
565not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 38/18 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
18Growth factors; Growth regulators
A61K 38/19 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
CPC
A61K 31/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
A61K 31/445
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
445Non condensed piperidines, e.g. piperocaine
A61K 31/565
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
565not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
A61K 38/22
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
Applicants
  • NEURONZ LIMITED [NZ]/[NZ]
  • FREYBERG, Derek, P. [US]/[US] (MZ)
Inventors
  • HUGHES, Paul, E.
  • FERNANDEZ, John, Anthony, Cajetan
  • RANIGA, Sumit
Agents
  • MEYER, Sheldon, R.
Priority Data
60/300,51422.06.2001US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) NEUROPROTECTION AND/OR NEURORESTORATION VIA THE NEURAL AVTIVIN TYPE IIB RECEPTOR
(FR) NEUROPROTECTION ET/OU NEURORESTORATION VIA LE RECEPTEUR DE L'ACTIVINE NEURALE DE TYPE IIB
Abstract
(EN) The neural Type IIB activin receptor (ActRIIB) is strongly expressed in the injured brain, in contrast to the near absence of its expression in the uninjured, non-diseased brain. This invention is directed to the use of ActRIIB activating agents and disinhibiting agents in treating neuronal insult (including stroke). This invention provides agents and methods of using agents that activate or disinhibit ActRIIB, and associated intracellular signaling pathways, as neuroprotective and neurorestorative agents that are specifically targeted to the injured brain and selectively to injured regions of the brain.
(FR) L'invention concerne un récepteur de l'activine neurale de type IIB (ActRIIB) fortement exprimé dans un cerveau blessé alors qu'il ne l'est et pratiquement pas dans un cerveau non blessé, non malade. L'invention concerne également l'utilisation d'agents d'activation et de disinhibition de ActRIIB pour traiter une agression neuronale (notamment un accident cérébrovasculaire). L'invention concerne des agents et de méthodes utilisant lesdits agents pour activer ou disinhiber ActRIIB, et des chemins de signalisation intracellulaires associés utilisés comme agents neuroprotecteurs et neurorestorateurs ciblant spécifiquement le cerveau blessé et sélectivement des régions blessées du cerveau.
Related patent documents
US20030103959
AU2002315441
Latest bibliographic data on file with the International Bureau
# -